Mondelēz International vs Revolution Beauty

Mondelēz International Announces Toblerone Diamond Truffles with Biscoff®, Uniting Two Global Icons in a Premium Chocolate Experience

Toblerone Diamond Truffles with Biscoff® combine smooth Toblerone milk chocolate, rich Biscoff® spread filling, and crunchy honey-almond nougat pieces in a distinctive diamond shape. Available in two formats: a 495g premium box exclusive to Costco across ten markets, and a 180g sharing box in select countries. Marks the first global retail partnership between Mondelēz International and Costco.

10-Q Financial Filing Analysis for Mondelēz International (2026-07-28)

For the second quarter ended June 30, 2026, Mondelēz International reported net revenues of $9.36 billion, an increase of 4.1% year-over-year (with Organic Net Revenue growing 2.2%), driven by carryover pricing and volume/mix gains across emerging markets. Operating income rose 66.0% to $1.95 billion, and net earnings attributable to Mondelēz reached $1.55 billion ($1.20 diluted EPS), substantially elevated by mark-to-market derivative gains of $827 million and lower pension settlement costs compared to the prior-year period. However, Adjusted Operating Income decreased 4.8% to $1.22 billion (and down 6.1% on constant currency) due to higher raw material input costs, pricing elasticity headwinds in Europe, and ERP transformation expenditures.

• Net revenues for Q2 2026 increased 4.1% to $9,355 million, with Organic Net Revenue rising 2.2% driven by 1.5 pp of pricing and 0.7 pp of volume/mix.
• Reported operating income reached $1,946 million (20.8% margin) up from $1,172 million, boosted by $827 million in mark-to-market derivative gains, while Adjusted Operating Income declined 4.8% to $1,222 million.
• Quarterly cash dividend was raised by 4% to $0.52 per share of Class A Common Stock, payable on October 14, 2026, with $6.5 billion remaining under the share repurchase program.

8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)

On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.

• CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
• Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
• Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.